The stock will likely react negatively to the significant EPS miss and lowered revenue guidance, despite maintained EBITDA targets. Monitor pharma marketing trends and AI cost savings execution. The insider buying spree ($28.8M in 30 days) suggests confidence in the long-term thesis, but near-term headwinds are clear.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $9.15entry
- T+1 · 7mo ago −0.98%α −1.05% · $9.06
- T+5 · 7mo ago −6.45%α −10.58% · $8.56
- T+20 · 7mo ago +5.68%α −3.30% · $9.67
- T+60 · 5mo ago +17.16%α +3.69% · $10.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Phreesia reported Q4 revenue of $127.1M (16% YoY growth) but missed EPS estimates with $0.02 vs $0.31 expected, driven by higher costs. The company lowered its FY2027 revenue guidance to $510-520M (from $545-559M) due to reduced pharma marketing spend, particularly in vaccines and GLP-1 drugs, but maintained its Adjusted EBITDA guidance of $125-135M through cost efficiencies from AI-driven automation.
Key Financial Metrics
Key Facts
- Q4 revenue: $127.1M (+16% YoY), but EPS of $0.02 missed consensus of $0.31 by 93.5%
- Lowered FY2027 revenue guidance to $510-520M (down $35-49M) due to reduced pharma client spending commitments
- Maintained Adjusted EBITDA guidance of $125-135M despite revenue cut, citing AI-driven efficiency gains
- Network solutions revenue under pressure from vaccine and GLP-1 drug marketing pullbacks
- AccessOne acquisition contributing as expected; refinancing completed with new $275M credit facility
Financial Impact
Revenue guidance reduced by $35-49M; EBITDA margin expansion expected to offset most of the decline
Risk Factors
- Continued weakness in pharma marketing spend could lead to further guidance cuts
- AI-driven cost savings may not materialize as quickly or fully as expected
- Execution risk in integrating AccessOne and scaling ProviderConnect
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001412408-26-000084 |
| Document: phr-20260330.htm | 0001412408-26-000084 |
| Document: 0001412408-26-000084-index-headers.html | 0001412408-26-000084 |
| Document: 0001412408-26-000084-index.html | 0001412408-26-000084 |
| Document: 0001412408-26-000084.txt | 0001412408-26-000084 |
| 8-K Data (Synthetic) | 0001412408-26-000084 |
Track record
8 reports on PHR
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +9.28% at T+20 after the Sep 2, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 4/10 Entry $12.69 Now $12.82 −1.02% settles Nov 20
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $12.37 to $13.18 Now $12.82 +3.64% ▲ +6.55% +7.26% vs SPY
- Sep 2, 202610w ago 8-K Bearish 6/10 Entry $11.10 to $10.31 Now $12.82 −15.50% ▲ +7.12% +5.97% vs SPY
- May 14, 202626w ago DEFA14A Neutral 3/10 Entry $8.77 to $8.92 Now $12.82 +46.18% ▲ +1.71% +0.75% vs SPY
- Apr 10, 202631w ago Insider Cluster Bearish 4/10 Entry $8.06 to $9.17 Now $12.82 −59.06% ▼ −13.77% −9.27% vs SPY
- Apr 10, 202631w ago Insider Cluster Bearish 6/10 Entry $8.06 to $9.17 Now $12.82 −59.06% ▼ −13.77% −9.27% vs SPY
- Apr 3, 202632w ago 8-K Bearish 8/10 Viewing Entry $9.15 to $8.56 Now $12.82 −40.11% ▲ +6.45% +10.58% vs SPY
- Mar 18, 202634w ago Insider Cluster Neutral 4/10 Entry $11.20 to $11.28 Now $12.82 +14.46% ▲ +0.71% +1.43% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers